Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Summary: Our understanding of the mechanisms that regulate hematopoietic stem/progenitor cells (HSPCs) has been advanced by the ability to genetically manipulate mice; however, germline modification is time consuming and expensive. Here, we describe fast, efficient, and cost-effective methods to dir...

Full description

Bibliographic Details
Main Authors: Michael C. Gundry, Lorenzo Brunetti, Angelique Lin, Allison E. Mayle, Ayumi Kitano, Dimitrios Wagner, Joanne I. Hsu, Kevin A. Hoegenauer, Cliona M. Rooney, Margaret A. Goodell, Daisuke Nakada
Format: Article
Language:English
Published: Elsevier 2016-10-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124716313687
id doaj-a84ef1ca22b448db80fbb63ddf1b86b6
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Michael C. Gundry
Lorenzo Brunetti
Angelique Lin
Allison E. Mayle
Ayumi Kitano
Dimitrios Wagner
Joanne I. Hsu
Kevin A. Hoegenauer
Cliona M. Rooney
Margaret A. Goodell
Daisuke Nakada
spellingShingle Michael C. Gundry
Lorenzo Brunetti
Angelique Lin
Allison E. Mayle
Ayumi Kitano
Dimitrios Wagner
Joanne I. Hsu
Kevin A. Hoegenauer
Cliona M. Rooney
Margaret A. Goodell
Daisuke Nakada
Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
Cell Reports
author_facet Michael C. Gundry
Lorenzo Brunetti
Angelique Lin
Allison E. Mayle
Ayumi Kitano
Dimitrios Wagner
Joanne I. Hsu
Kevin A. Hoegenauer
Cliona M. Rooney
Margaret A. Goodell
Daisuke Nakada
author_sort Michael C. Gundry
title Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
title_short Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
title_full Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
title_fullStr Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
title_full_unstemmed Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
title_sort highly efficient genome editing of murine and human hematopoietic progenitor cells by crispr/cas9
publisher Elsevier
series Cell Reports
issn 2211-1247
publishDate 2016-10-01
description Summary: Our understanding of the mechanisms that regulate hematopoietic stem/progenitor cells (HSPCs) has been advanced by the ability to genetically manipulate mice; however, germline modification is time consuming and expensive. Here, we describe fast, efficient, and cost-effective methods to directly modify the genomes of mouse and human HSPCs using the CRISPR/Cas9 system. Using plasmid and virus-free delivery of guide RNAs alone into Cas9-expressing HSPCs or Cas9-guide RNA ribonucleoprotein (RNP) complexes into wild-type cells, we have achieved extremely efficient gene disruption in primary HSPCs from mouse (>60%) and human (∼75%). These techniques enabled rapid evaluation of the functional effects of gene loss of Eed, Suz12, and DNMT3A. We also achieved homology-directed repair in primary human HSPCs (>20%). These methods will significantly expand applications for CRISPR/Cas9 technologies for studying normal and malignant hematopoiesis. : Gundry et al. develop an efficient and simple method implementing CRISPR/Cas9-mediated gene disruption and HDR in murine and human HSPCs. This method enables quick evaluation of the function of genes by performing in vitro or transplantation assays using the modified HSPCs. Keywords: HSC, hematopoietic stem cells, progenitor, human CD34, genome editing, CRISPR/Cas9, sgRNA, homology-directed repair, gene therapy, transplantation
url http://www.sciencedirect.com/science/article/pii/S2211124716313687
work_keys_str_mv AT michaelcgundry highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT lorenzobrunetti highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT angeliquelin highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT allisonemayle highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT ayumikitano highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT dimitrioswagner highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT joanneihsu highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT kevinahoegenauer highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT clionamrooney highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT margaretagoodell highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
AT daisukenakada highlyefficientgenomeeditingofmurineandhumanhematopoieticprogenitorcellsbycrisprcas9
_version_ 1725050723567140864
spelling doaj-a84ef1ca22b448db80fbb63ddf1b86b62020-11-25T01:39:03ZengElsevierCell Reports2211-12472016-10-0117514531461Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9Michael C. Gundry0Lorenzo Brunetti1Angelique Lin2Allison E. Mayle3Ayumi Kitano4Dimitrios Wagner5Joanne I. Hsu6Kevin A. Hoegenauer7Cliona M. Rooney8Margaret A. Goodell9Daisuke Nakada10Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USAStem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, 06156 Perugia, ItalyDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX 77030, USADepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USADepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USACenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX 77030, USA; Institute for Medical Immunology, Charité University Medicine Berlin, 13353 Berlin, GermanyStem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Translational Biology and Molecular Medicine Program, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USADepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USACenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX 77030, USADepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX 77030, USA; Corresponding authorDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Corresponding authorSummary: Our understanding of the mechanisms that regulate hematopoietic stem/progenitor cells (HSPCs) has been advanced by the ability to genetically manipulate mice; however, germline modification is time consuming and expensive. Here, we describe fast, efficient, and cost-effective methods to directly modify the genomes of mouse and human HSPCs using the CRISPR/Cas9 system. Using plasmid and virus-free delivery of guide RNAs alone into Cas9-expressing HSPCs or Cas9-guide RNA ribonucleoprotein (RNP) complexes into wild-type cells, we have achieved extremely efficient gene disruption in primary HSPCs from mouse (>60%) and human (∼75%). These techniques enabled rapid evaluation of the functional effects of gene loss of Eed, Suz12, and DNMT3A. We also achieved homology-directed repair in primary human HSPCs (>20%). These methods will significantly expand applications for CRISPR/Cas9 technologies for studying normal and malignant hematopoiesis. : Gundry et al. develop an efficient and simple method implementing CRISPR/Cas9-mediated gene disruption and HDR in murine and human HSPCs. This method enables quick evaluation of the function of genes by performing in vitro or transplantation assays using the modified HSPCs. Keywords: HSC, hematopoietic stem cells, progenitor, human CD34, genome editing, CRISPR/Cas9, sgRNA, homology-directed repair, gene therapy, transplantationhttp://www.sciencedirect.com/science/article/pii/S2211124716313687